Biogen, Inc.’s new president and CEO Christopher Viehbacher has brought in former Sanofi colleague Adam Keeney to help advance the company’s goal of “sustainable growth” from its existing products and programs as well as from assets sourced externally. Keeney, Biogen’s newly appointed executive vice president and head of corporate development, told Scrip he is encouraged by what the company already is working on and is looking forward to bringing novel therapies into the mix.
Biogen’s Adam Keeney Focuses On Dealmaking As Growth Strategy Is Made Over
Sanofi Alum Is New Addition To Executive Committee
Recently appointed head of corporate development in an ongoing leadership shakeup, Keeney is helping to shape Biogen’s sustainable growth strategy in neuroscience and beyond.
More from Deals
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.